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Background: A lack of defined correlates of immunity for malaria, combined with the inability to induce long-lived
sterile immune responses in a human host, demonstrate a need for improved understanding of potentially
protective immune mechanisms for enhanced vaccine efficacy. Protective sterile immunity (>90%) against the
Plasmodium falciparum circumsporozoite protein (CSP) has been achieved using a transgenically modified
Plasmodium berghei sporozoite (Tg-Pb/PfCSP) and a self-assembling protein nanoparticle (SAPN) vaccine presenting
CSP epitopes (PfCSP-SAPN). Here, several possible mechanisms involved in the independently protective humoral
and cellular responses induced following SAPN immunization are described.
Methods: Inbred mice were vaccinated with PfCSP-SAPN in PBS. Serum antibodies were harvested and effects on
P. falciparum sporozoites mobility and integrity were examined using phase contrast microscopy. The functionality
of SAPN-induced antibodies on inhibition of sporozoite invasion and growth within primary human hepatocytes
was also examined. The internal processing of SAPN by bone marrow-derived dendritic cells (BMDDC), using
organelle-specific, fluorescent-tagged antibody or gold-encapsulated SAPN, was observed using confocal or
electron microscopy, respectively.
Results: The results of this work demonstrate that PfCSP-SAPN induces epitope-specific antibody titers,
predominantly of the Th2 isotype IgG1, and that serum antibodies from PfCSP-SAPN-immunized mice appear to
target P. falciparum sporozoites via the classical pathway of complement. This results in sporozoite death as
indicated by cessation of motility and the circumsporozoite precipitation reaction. Moreover, PfCSP-SAPN-induced
antibodies are able to inhibit wild-type P. falciparum sporozoite invasion and growth within cultured primary
human hepatocytes. In addition, the observation that PfCSP-SAPN are processed (and presented) to the immune
system by dendritic cells in a slow and continuous fashion via transporter associated with antigen processing (TAP)
recruitment to the early endosome (EE), and have partially delayed processing through the endoplasmic reticulum,
has the potential to induce the long-lived, effector memory CD8+ T-cells as described previously.
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Conclusion: This paper describes the examination of humoral and cellular immune mechanisms induced by
PfCSP-SAPN vaccination which result in sterile host protection against a transgenic P. berghei malaria sporozoite
expressing the P. falciparum CSP, and which significantly inhibits native P. falciparum sporozoites from invading
and developing within cultured human hepatocytes. These results may indicate the type and mode of action of
protective antibodies needed to control P. falciparum sporozoites from infecting humans as well as a potential
mechanism of induction of protective long-lived effector memory CD8+ T-cells.
Keywords: Self-assembling protein nanoparticle, Plasmodium, Vaccine, Erythrocytic stage, Circumsporozoite protein,
TAP, Dendritic cells, Complement lysisBackground
The most basic and desirable outcome of a successful
vaccine is that it will induce sterile and long-lived immunity
in the host. Historically, with most vaccines, this result has
been best achieved through the use of chemically fixed,
heat-killed or live-attenuated organisms. In the case of mal-
aria this approach has been relatively unsuccessful but
more interest has recently been dedicated to these methods
[1-3]. Recombinant subunit protein vaccines targeting
various parasite proteins of choice, used in combination
with immune-boosting adjuvants, have been examined and
have yielded promising but limited results. The vaccine
RTS,S, currently in Phase 3 human trials, is a subunit
circumsporozoite protein (CSP) linked to the Hepatitis B
surface protein (HBSP) which self-assembles with native
HBSP to form a virus-like particle. RTS,S vaccination has
resulted in somewhat reduced clinical infection [4,5].
Longevity studies examining the observed reduced parasite
loads, as well as more detailed investigations into possible
correlates of this protection, will hopefully be forthcoming
in the next few years to further evaluate this vaccine
delivery platform.
Malaria vaccinology suffers from a lack of understanding
of viable mechanisms by which the host’s immune system
is able to efficiently respond to such a highly polymorphic
parasite. Even naturally acquired immunity is slow to
develop and is easily lost [6]. There is little evidence to sup-
port correlations of vaccine-induced human Plasmodium
immunity or sterile protection from vaccines for malaria. If
we could understand, induce and/or manipulate effective
mechanisms that would lead to complete protection and
long-lived immunity against Plasmodium infection, we may
be better armed to improve on or design novel vaccine plat-
forms that could enhance host immunity to this end. The
studies presented here are an investigation into the mecha-
nisms behind the efficacy of a novel type of immunogen, a
self-assembling protein nanoparticle (SAPN) [7-9]. These
SAPN have been successfully used to deliver Plasmodium
falciparum CSP-derived T- and B-cell epitopes to generate
a protective immune response against malaria, which is
believed to act, in part, by enhanced repetitive display of
highly immunogenic peptides [10,11].The innate immune system can be a critical player in
effective immunity to malaria infection [12]. Innate
mechanisms of protection are the first and most non-
specific immunity the host has in its arsenal against a
primary infection. These initial mechanisms link and re-
late tailored responses that are required to properly and
effectively protect against secondary infections. Other
than the use of some poorly understood classes of adju-
vants, little is known about the specific initial responses
required, in conjunction with vaccine administration, to
provide complete protection against human malaria infec-
tion. The innate system, targeted in synergy with adaptive
immune responses, can often outweigh the immunological
importance of either in isolation [12]. Various vaccines
have demonstrated potential roles for non-specific media-
tors such as secreted factors and cells in managing malaria
infection [13-16], but more may be required from both
branches of the immune system in terms of understanding
and promoting “cross-talk” between branches to achieve
an efficacious vaccine product against human malaria.
To improve this understanding, and enhance an aware-
ness of potential avenues for boosting vaccine efficacy, this
paper examines several interactions between innate and
adaptive immunity following SAPN immunization. The
results show that SAPN-induced antibodies exhibit an
ability to inhibit motility and induce complement (C’) lysis
of malaria parasites prior to liver infection. Moreover,
tracking fluorescently labeled or gold-tagged SAPN dem-
onstrate a delayed processing and (presentation) of
PfCSP-SAPN by dendritic cells that may help explain the
induction of the previously reported highly effective and
long-lived adaptive cellular responses [11].Methods
Vaccines
SAPN were synthesized and assembled as previously
described [11]. Gold-encapsulating SAPN were synthesized
[17] by first denaturing PfCSP-SAPN overnight in 9 M
urea, 20 mM HEPES, pH 7.5, 50 mM NaCl, 5% glycerol.
Next, the protein monomers were concentrated to 1 mg/ml
using Amicon MWCO 3000. After concentration the
monomers were diluted 20-fold into 20 mM HEPES,
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citrate-coated gold nanoparticles (Nanocs, Inc via Thermo
Fisher Scientific, Inc, Pittsburgh, PA, USA). The final molar
ratio of protein chains per gold nanoparticle was 420:1.
Dialysis was performed overnight in 20 mM HEPES,
pH 7.5, 50 mM NaCl, 5% glycerol to remove the remaining
urea. The gold-encapsulating SAPN were characterized by
transmission electron microscopy (TEM) and dynamic
light scattering (DLS).
PfCSP-SAPN displayed the (NANP) central repeat
peptide of the PfCSP; the PfCSP-KMY-SAPN [11] also
displayed the central repeat peptide but, in addition,
contained 3 CD8+ T-cell epitopes from the Pf CSP. PvCSP-
SAPN contained the same scaffold as Pf CSP but displayed
the Plasmodium vivax CSP central repeat peptide [11].
Immunizations
Female C57BL/6 mice five to six weeks of age, sex- and
age-matched from the Jackson Laboratory (Bar Harbor,
ME, USA) were injected ip or im with 10 μg/mouse
PfCSP-SAPN or sterile saline, for a total of three immuni-
zations administered two weeks apart. Blood was drawn
for antibody analysis one day prior to each immunization
and two weeks post final immunization via tail vein nick.
All animal protocols were conducted following review and
approval by the WRAIR IACUC.
ELISA
Serum antibody levels were determined following
PfCSP-SAPN immunization by ELISA. Anti-PfCSP anti-
body isotype profiles were determined using IgG1, IgG2c,
IgG3 and IgE isotype-specific goat anti-mouse horseradish
peroxidase-tagged secondary antibodies (Southern Biotech,
Birmingham, AL, USA). Color change was initiated with
ABTS Peroxidase Solution (KPL, Gaithersburg, MD, USA)
and analysed by absorbance OD405 =1.
Cell culture
Bone marrow was flushed from the femurs of C57BL/6
mice using a 26G needle syringe and cultured for nine days
at a concentration of 1.5 × 106 cells/ml in RPMI complete
media in the presence of 200 ng/ml recombinant murine
Flt3-Ligand (BioVision, Mountain View, CA, USA) and
20 ng/ml recombinant human GM-CSF or 20 ng/ml
recombinant human GM-CSF and 20 ng/ml recombinant
human IL-4 (both from PeproTech, Inc, Rocky Hill, NJ,
USA) in 24 well plates, for a final purity consistent with pre-
vious studies using Flt3-Ligand [18]. Cells were maintained
and used on day nine or ten of culture and treated/handled
as described for flow cytometry and microscopy.
Flow cytometry
Surface staining of bone marrow-derived dendritic cells
(BMDDCs) was performed and evaluated by flow cytometrywith antibodies recognizing CD8α, CD11b, CD11c, CD103
and CD207. All antibodies were obtained through
BD Biosciences (San Jose, CA, USA) or e-Biosciences
(San Diego, CA, USA).
Confocal microscopy
BMDDCs were harvested from culture, transferred to
eight-well chamber slides, and allowed to adhere overnight
in the presence of 5 μl early endosome (EE) marker,
(Invitrogen, Eugene, OR, USA), 6.67 ng/ml in house-
labeled SAV-TAP, and/or 5 × 10-6 mmol Lysotracker
(Invitrogen, Eugene, OR, USA) in a final staining volume of
2.5-7.5 × 105 cells/150 μl/well. Cells were also co-cultured
with 1.5 μg/ml of in-house TAMRA-5-labeled SAPN or
ovalbumin at ten-minute, two-hour and overnight time
points. Slides were washed, fixed with methanol or 4% PAF
and DAPI was added prior to coverslipping. Analysis was
performed using confocal microscopy.
Electron microscopy
BMDDCs were co-cultured with 20–50 μg/ml either in-
house gold-encapsulating SAPN ovalbumin or gold alone
overnight and then harvested from culture and spun at
300×g for eight minutes. SAPN and ovalbumin samples
are processed differently from this step forward. The SAPN
cell pellet was resuspended in refrigerated 1% glutaralde-
hyde, 4% paraformaldehyde fixative for one hour at room
temperature. Samples were post-fixed in 2% osmium tet-
roxide for forty-five minutes, embedded in Epon® embed-
ding media and mounted on copper grids. Ovalbumin cell
pellets were resuspended in refrigerated 0.1% glutaralde-
hyde, 4% paraformaldehyde fixative for one hour at room
temperature, embedded in LR white medium, mounted on
200-mesh grids, and were given a secondary labeling of
1:25 anti-ovalbumin (Abcam, Cambridge, MA, USA) and
1:10 colloidal gold-labeling (Insight Genomics, Falls
Church, VA, USA). All samples were post-stained with 2%
uranyl acetate for twenty minutes and lead citrate for five
minutes at room temperature. Samples were then analysed
by transmission electron microscopy on a Jeol 100CX
Electron Microscope.
Complement analysis
Anopheles stephensi mosquitoes infected with P. falciparum
sporozoites were sacrificed by submersion in 70% ETOH.
Salivary glands were dissected and processed using the
Ozaki method for sporozoite isolation. 1 × 105 sporozoites
were placed in 80% of either: serum from PfCSP-SAPN
immunized animals, PfCSP-SAPN immunized mouse
serum containing ethylenediaminetetraacetic acid (EDTA)
to chelate Ca2+, heat inactivated PfCSP-SAPN serum
(heated at 56°C for forty-five minutes) or in serum from
saline immunized animals in pre-warmed 96-well,
round-bottom plates for twenty minutes at 37°C. 5–10 μl
Figure 1 PfCSP-SAPN-induced antibodies are predominantly
Th2 skewed. PfCSP-SAPN were given by i.m. injection into C57BL/6
mice and serum was collected two weeks post third immunization and
analysed for anti-PfCSP specific antibody isotype titers. Results are
shown for three independent experiments, 10 mice per group.
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and analysed by phase contrast microscopy at 20× or
67× magnification.
Immunofluorescence assay
Room temperature immunofluorescence assay (IFA) slides
were processed by adding 25 μl/well of diluted serum
sample 1:20 and incubated for one hour at 37°C and then
washed three times by soaking slides in a reservoir of
1× PBS. After washing 25 μl/well of the secondary
antibody, FITC-labeled goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories, Inc, West Grove, PA, USA),
was then added at a 1:40 dilution in 1% Evans Blue solution
and the slide was incubated for thirty minutes at 37°C. The
slide was then washed again three times in 1× PBS as
described previously and allowed to air dry. Vectashield
(Vector Laboratories, Inc, Burlingame, CA, USA) was
then added to each well and slides were analysed
under fluorescent microscope.
Inhibition of liver stage development assay
2 × 105 cyropreserved primary human hepatocytes (CPHH)
in 100 μL culture media [19,20] were plated, in triplicate, to
confluency onto collagen-coated, eight-chamber LAB-TEK
slides and incubated overnight. The next day P. falciparum
sporozoites were collected by salivary gland dissection; 2.5 ×
105 sporozoites were incubated at room temperature for
twenty minutes with a 1:50 dilution of the indicated serum
or with the positive control, NFS-1, a mouse IgG1 mono-
clonal antibody to P. falciparum repeats [21] and then
added into the wells containing CPHH and incubated at
37°C for three hours to allow sporozoites to infect
CPHH. After the three-hour incubation period, CPHH
were washed with fresh culture media to remove
non-invaded sporozoites. CPHH were harvested on
day 4. Upon harvesting, CPHH were trypsinized for
fifteen minutes and washed twice: once with fresh
media and then with Hank’s balanced salt solution
(HBSS). A low speed spin (1,200 rpm for two minutes)
was performed between each wash to remove external
adherent sporozoites, which remain in the supernatant,
and the resulting cell pellet was collected. A quantitative
real-time PCR (qRT-PCR) was used to determine the
invasion/development rate. For every assay, a standard
curve was generated using known numbers of sporo-
zoites (ranging from 4,860 to 20, 1:3 serial dilutions).
The qRT-PCR data of each sample were compared to the
standard curve and quantified. The invasion/development
rate of each test (IT) sample is compared to the invasion/
development rate of the negative control (IC) to give
a percent inhibition.
%Inv or Dev ¼ Ic−ITð Þ=Ic  100Results
PfCSP-SAPN-induced antibodies are predominantly Th2
skewed and bind Plasmodium falciparum sporozoites
Recently published findings have found that self-assembling
protein nanoparticles containing peptide sequences (NANP)4
from the central repeat region of the circumsporozoite
protein of P. falciparum induced antibody that was able to
sterilely protect mice against lethal challenge [11]. These
studies, which looked at the immune response against
human malaria P. falciparum CSP, were possible to do in
a murine model using a transgenic Plasmodium berghei
sporozoite that has had the full-length circumsporozoite
protein (csp) gene replaced with that of P. falciparum [22].
Thus, PfCSP-SAPN induced antibodies derived in
mice are specific for the CSP protein of the human
parasite, P. falciparum. As IgG1 is a known stimulator of
C’ [23], it was undertaken here to demonstrate if the
SAPN-induced antibodies were of a particular isotype and
if the classical pathway of C’ was involved in protection.
Examination of the antibody isotype profiles derived from
SAPN-immunization show a significant predominance of
anti-CSP Th2-type IgG1 antibodies (Figure 1). While it was
demonstrated that the induction of antibodies that bind to
the PfCSP repeat sequence expressed on the genetically
modified P. berghei parasite, and to a synthetic amino acid
sequence bound to a microtiter plate, it was important to
determine if the antibodies induced by the SAPN vaccine
also bound to CSP on native P. falciparum sporozoites This
was demonstrated by an IFA (Figure 2). Thus, observing
that SAPN-induced antibodies were able to bind P.
falciparum sporozoites, and with the understanding that
IgG1 is able to induce the C’ cascade [23], the question was
whether SAPN-induced antibodies would be able to
activate C’ and have an effect on P. falciparum sporozoites.
Figure 2 Immunofluorescence assay of Plasmodium falciparum
sporozoites incubated with PfCSP-SAPN immune sera at a 1:20
dilution. Preimmune sera from the mice, sera from PvCSP-SAPN
immunized mice, and secondary antibody only sera tests resulted in
negative immunofluorescence.
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morphology of Plasmodium falciparum sporozoites and
prevent invasion into human hepatocytes
In order to examine the potential role of antibody-induced
C’ induction in sporozoite killing, the morphology of
P. falciparum sporozoites was examined following co-
incubation with or without serum containing CSP-specific
antibodies derived from PfCSP-SAPN immunization.
Within five minutes of co-incubation it was observed that
the immune serum hampered or halted sporozoite motilityFigure 3 Plasmodium falciparum sporozoite morphology is altered by
sporozoites were incubated with either PfCSP-SAPN immunized serum take
A) treated to remove Ca2+ ions (Panel B), serum from (Panel A) heat-inactiv
mice (Panel D), or serum from mice immunized with PvCSP-SAPN two wee
five independent experimentsand phase contrast microscopy demonstrated that after five
to twenty minutes of co-incubation there were obvious
morphological changes between parasites treated with
serum from PfCSP-SAPN immunized mice and control
sera (Figure 3, Panels A, D). These changes included the
appearance of “blebbing”, or bulbous bulges at the apex of
the parasites, “hooked” end phenotypes and elongation and
thinning of the parasites. Moreover, if EDTA was added to
serum to chelate calcium ions, which are required for the
induction of the classical but not the alternative pathway of
complement, the normal parasite phenotype was main-
tained (Figure 3, Panel B). This indicated, specifically, that
the classical pathway of complement was involved in the
altered morphology and apparent destruction of parasites
by PfCSP-SAPN-induced anti-CSP antibodies. Although
not sufficient to prove this pathway is solely or uniquely
involved in this process, it is a strong indication as to its
importance under these conditions. To confirm that with-
out C’ the observed effects on morphology were absent,
heat-inactivation of the same serum from PfCSP-SAPN
immunized animals was co-incubated with P. falciparum
sporozoites. After this treatment no alteration of sporozoite
phenotype was observed (Figure 3, Panel C). The classical
pathway of C’ present in sera, moreover, was not able to
affect these changes in morphology in the absence of
PfCSP-SAPN-induced antibodies (Figure 3, Panel D), nor
did serum from mice immunized with a PvCSP-SAPN [11]
presenting the P. vivax CSP repeat peptide, (Figure 3,
Panel E). These findings, collectively, indicate that PfCSP-
SAPN antibodies are specifically able to activate andanti-PfCSP-SAPN serum antibodies. Plasmodium falciparum
n two weeks post third immunization (Panel A) or serum from (Panel
ated in order to inactivate C’ (Panel C), serum from PBS-immunized
ks post third immunization (Panel E). Representative images shown;
McCoy et al. Malaria Journal 2013, 12:136 Page 6 of 11
http://www.malariajournal.com/content/12/1/136induce changes in the morphology of P. falciparum sporo-
zoites by the induction of the classical pathway of C’.
To further examine how SAPN-induced CSP-specific
antibodies were able to inhibit P. falciparum parasites
a series of inhibition of liver stage development assays
(ILSDA) were performed using primary human hepa-
tocytes. As shown in Figure 4, there was an antibody-
dependent inhibition of the parasites developing
inside the liver cells when sporozoites were exposed
to serum from PfCSP-SAPN-immunized mice. This
inhibition was not observed when using serum from
PvCSP-SAPN or PBS-sham immunized mice. From
this test alone it cannot be determined if the resulting
reduction of parasites developing inside the liver cells
was due to an inhibition of invasion or an impairment of
growth after invasion. However, combined with the
microscopic observations reported above (Figure 3)
of sporozoite morphological changes in the presence of
PfCSP-SAPN immune sera, this strongly suggests the
reduction in parasite 18S RNA in the liver cells was
the result of fewer sporozoites invading the cells after
exposure to immune sera.Figure 4 PfCSP-SAPN-induced antibody is able to deter
sporozoite liver stage development in a concentration
dependent manner. Human hepatocytes cultured in the
presence of P. falciparum sporozoites and serum from either
PfCSP-SAPN-immunized mice (at 1:20, 1:200, or 1:1,000 dilution),
PvCSP-SAPN immunized mice (1:20 dilution) or PBS-sham
immunized mice (1:20 dilution). Shown are the reductions in the
percent of infected hepatocytes following four days in culture
compared to the PBS (1:20 dilution) incubated controls. Error bars
are the SD of the mean; PfCSP-SAPN and PvCSP-SAPN at 1:20
dilution show significance using Student’s t-test.Protective adaptive immunity may be the result of
delayed antigen processing and presentation of SAPN to
CD8+ T-lymphocytes
In addition to better understanding the nuances of the
humoral responses derived by SAPN immunization, it was
also undertaken to understand the way in which PfCSP-
SAPN processing and presentation by innate immune cells
is able to stimulate the previously observed highly effective
and long-lived adaptive cellular responses [11]. By analysing
in vitro BMDDC by microscopy, the specific kinetics of
SAPN processing through BMDDCs could be examined.
Results of confocal microscopy show that SAPN have
delayed processing in EE organelles, which can last up to
twenty-four hours. When compared to a classically
processed reference protein, ovalbumin, which is rapidly
processed through the endoplasmic reticulum after ten
minutes (Figure 5, Panels A-D), the timing is consistent
with a cross-presenting mechanism for SAPN, which has
the potential to enhance resulting cellular immunity and
memory responses. The continuous recruitment of TAP to
the EE indicates that SAPN are highly localized (with TAP)
for extended time periods at the organelle membrane,
which would support the hypothesis of extended loading of
SAPN peptides to MHC class I molecules (Figure 5,
Panel D). While some SAPN were processed through the
lysosome at expected rates, there was a continued process-
ing of SAPN well beyond that of ova in BMDDCs, even up
to twenty-four hours (Figure 5, Panels C, D). Differential
and delayed processing of SAPN was further confirmed
using transmission electron microscopy (TEM), which de-
lineated the segregation of SAPN particles within the
late endosome/lysosome fusion organelle up to twenty-
four hours following stimulation (Figure 6, Panel A),
which was not merely a result of the colloidal gold encap-
sulation (Figure 6, Panel C). Furthermore, SAPN particles
demonstrated delayed interactions with lysosomal en-
zymes, even though the majority of the reference protein,
ova, almost completed its interactions and processing
through the organelle at this time point (Figure 6, Panels
A, B). Thus this characterization of the ability of SAPN to
maintain prolonged processing and loading of antigenic
peptides onto MHC class I molecules in the EE via
recruitment of TAP, could ultimately offer a substantial
enhancement to the induction of long-lived CD8+
T-lymphocyte memory responses [24,25].
Discussion
The most challenging aspect of designing a vaccine is to
understand how to induce efficiently a long-lived and
sterilely protective immune response in a host. In the case
of malaria, the limited natural host immunity that is
observed in endemic areas is short lived if the person
leaves the exposure area. Thus, attempts to mimic natural
immune responses to infection and develop an effective
Figure 5 SAPN have continuous and delayed processing through the early endosome of dendritic cells. Confocal microscopy images
taken at either ten minutes (Panels A, B) or twenty-four hours (Panels C, D) following co-culture of bone marrow-derived dendritic cells and
either ovalbumin (Panels A, C) or PfCSP-SAPN (Panels B, D). Red is labeled Ova or SAPN; green is labeled EE, TAP or lysosomal protein; yellow is
the result of merged images of red labeled Ova or SAPN and the green organelle marker dye; blue is the DAPI nuclear stain. Representative
images shown; six independent experiments.
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had significant advances but limited overall success. A
major hindrance to this work is a lack of knowledge
of the specific correlates of immunity and mecha-
nisms of protection required for malaria infection.
Here a novel way of presenting immunogenic protein
epitopes to the host’s immune system is described.
Evidence for a mechanism of action of a sterilely protect-
ive vaccine against malaria using CSP-derived epitopes is
presented, and provides insight for an efficacy evaluation
of other malaria vaccines.SAPN-containing peptides derived from the sporozoite
CS protein, predicted to stimulate B- and T-lymphocytes,
were able to induce robust and long-lived responses against
P. falciparum in mice [10]. Analysis of the humoral
response in this model demonstrated that antibodies
produced by SAPN immunization were predominantly
skewed towards a Th2 phenotype (IgG1), which has been
shown to induce activation of the classical pathway of
the complement cascade. The hypothesis that anti-
CSP antibodies could bind and alter the morphology
of sporozoites was first proposed three decades ago
Figure 6 SAPN have delayed organelle fusion and interaction with lysosomal enzymes. TEM images after twenty-four hours co-culture of
bone marrow-derived dendritic cells and gold-labeled PfCSP-SAPN (Panel A), ovalbumin (Panel B), or colloidal gold particles alone (Panel C).
White arrows indicate clusters of gold-encapsulated SAPN; black arrows indicate areas containing a high-density of lysosomal enzymes.
20–67 × magnifications shown. Representative images shown; six independent experiments.
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which observed the so-called “circumsporozoite pro-
tein reaction” or the “circumsporozoite precipitation
reaction” [27-29], the specific mechanism behind the
observed phenotypic changes was never fully elucidated.
The observations of incomplete CSP shedding may be the
result of the nature of the antibody isotype and activation
of C’ in a very specific fashion. While this study indirectly
demonstrates the role of C’ the use of specific inhibitors of
C’ activation [30] would be important to further corrobor-
ate the importance of the classical pathway in this process
of C’ action on sporozoite morphology and function. It was
observed here that SAPN-induced antibodies are able to
inhibit sporozoite motility, which may either act in con-
junction with C’ or by an as yet undetected mechanism
independent of C’. This effective concert between innate
and adaptive immune responses has the potential to elimin-
ate the majority of sporozoites as they migrate from the site
of injection by mosquito to the liver. The potent action ofSAPN-immunized serum antibodies, even at low titers [11],
indicates that antibodies induced by the SAPN are
able to affect shedding of CSP and target the parasite
for destruction. This demonstrates that a very high
concentration of antibodies may not be a critical re-
quirement for humoral protection of pre-erythrocytic
malaria vaccination schemes and suggests that the
quality of the antibody is more important than the
quantity. In support of this observation, Ferreira et al.
have shown that 10 μg/ml of antigen-specific anti-
bodies were able to neutralize greater than 98% of
injected parasites in a malaria infection model [27]
and Kaba et al. [11], in a year-long study demonstrated
100% protection of mice against sporozoite challenge if
SAPN-induced PfCSP-specific serum antibodies remained
above 7.3 μg/ml.
The ultimate power of this humoral response, how-
ever, was demonstrated by the ability of PfCSP-SAPN to
induce antibodies that prevent invasion and inhibit the
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within human hepatocytes. Thus, this SAPN induced
humoral response appears to be acting to: (1) suppress
parasite motility; (2) induce the activation of the classical
pathway of C’ for sporozoite lysis; and, (3) prevent the
invasion and growth of parasites in cultured human liver
hepatocytes.
The requirement for C’ is not absolute. Clearly the
literature has demonstrated anti-CSP monoclonal anti-
bodies, such as the positive control NSF-1 monoclo-
nal used in the ILSDA reported here work without
C’. But it must be emphasized that the selection of
these monoclonal antibodies did not include C’ in
the process.
An intriguing observation, however, is that even with-
out this humoral response, SAPN-induced cellular im-
munity is able to prevent blood-stage malaria infection
[11]. There are several factors that can aid in strong and
long-lived immune responses to antigen. Variables such
as mitogenicity, dosing and exposure times can all affect
the robustness of resulting host immunity. The SAPN is
about 35–40 nm in diameter, which allows it to easily
pass through the lymphatic system without the need to
be picked up and carried to the lymph nodes by anti-
gen presenting cells (APC). Once in the lymph node,
the exogenously-derived nanoparticles can be taken
up by the local predominant APC, the dendritic cell
(DC), and processed for loading onto MHC class I
molecules of CD8+ T-lymphocytes via a process
known as cross-presentation. The classical processing
of SAPN could be accounted for by the presence of
the universal pan CD4 helper epitope, PADRE, which
is included in the PfCSP-SAPN vaccine [11]. As little
evidence has been shown to demonstrate absolute
requirements for cross-presentation of proteins, only
a few things are commonly agreed on as important in
this process.
In the SAPN vaccine construct denoted as PfCSP-KMY-
SAPN, three CD8+ T-cell epitope peptides derived from
the PfCSP, in addition to the B-cell targeted epitopes of
the PfCSP repeat region, were used [11]. It is known that
the CSP aids in liver stage invasion and development
within the host, and it is believed that induction of a
primed CD8+ T-cell response in the liver results in
destruction of parasites that survived from the point of skin
infection to liver infiltration. The mechanisms by which
exogenously-delivered peptides are presented by the APC
to the T-cell antigen receptor of CD8+ T-lymphocytes to
induce T-cell priming has been one of the great enigmas
of immunology. Cross-presentation goes against the
dogma that primarily endogenously derived protein
epitopes are loaded to MHC class I molecules. If efficient
presentation of exogenously derived antigen could be
induced, it would enable highly efficient and robustresponses to multiple vaccination schemes and result in
enhanced host immunity. Although the nuances of SAPN
function are not yet completely understood, it is possible
that the ordered array of peptide sequences, the hydro-
phobic/hydrophilic nature and/or physical structure in-
trinsic to the SAPN design, as well as the dose of antigen
are all unique and effective at enabling cross-presentation
of SAPN peptides to the immune system. Through the
prolonged segregation and processing of SAPN, and
the recruitment of TAP to the EE, there is a much
stronger stimulation over an extended period of time
than that observed with classical soluble proteins,
such as ovalbumin. These observations give a much
better understanding of what mechanisms are trig-
gered by SAPN to induce and refine the long-lived
adaptive cellular immune responses observed following
SAPN vaccination [10,11].
In light of the confocal and TEM results presented here,
a model for the cross-presentation and processing of SAPN
within DC that may ultimately be responsible for the long-
lived B- and T-cell responses observed following SAPN
vaccination is put forward as a possible explanation. There
are several proposed models that describe the complex
mechanisms behind cross-presentation, we promote here
that the observed delayed and segregated SAPN process-
ing, as well as the recruitment of TAP to early endosome
organelles is a mechanism of cross-presentation taken
by SAPN. This enabled slow and continuous presen-
tation of antigen to the adaptive immune system.
Compared to the traditional model of direct shuttling
of cytoplasmic peptide to the endoplasmic reticulum
for loading onto MHC class I molecules, this model
of peptide processing promotes induction of long-
lived cellular responses to vaccine-delivered peptides.
Further processing of SAPN does appear to occur at
the lysosome/endoplasmic reticulum stage, which follows
the accepted model that CD4+ T-cell-predicted peptides
are processed and presented via MHC class II molecules in
a classical manner. Thus, evidence is presented here in sup-
port of a mechanism for cross-presentation which results
in the presence of long-lived memory CD8+ T-lymphocytes
as demonstrated previously [11].
Previous work has examined and proven the SAPN
platform as a viable method for inducing long-lived and
effective adaptive host immune responses in mice via the
delivery and processing of parasite antigens. Potential
improvements to this vaccine could be made with the
addition of an adjuvant in order to boost the magnitude of
the responses if needed in higher order mammals. Also,
the inclusion of sequences from other malaria strains,
such as the P. vivax CSP repeat sequence; or epitopes
from various P. falciparum proteins encompassing several
of the parasite life stages into a single platform could
enhance the scope of immunity.
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